ImmusanT Inc., a privately-held biotechnology company, said it has established its operations in Cambridge as it looks to develop an immunotherapeutic vaccine and a companion diagnostic and monitoring tool for celiac disease.
The company, which said in a press release that it has secured seed financing from angel investors, is calling its drug candidate vaccine Nexvax2. Celiac disease is a lifelong autoimmune disorder that is triggered by foods containing gluten, the main protein in wheat, rye, and barley."With the formation of ImmusanT in Cambridge, we will have broad access to resources, capital and potential partners required to advance development of Nexvax2 and our companion diagnostics," Leslie J. Williams, founder, president, and chief executive, said in a statement.
Link to article.